Physician profile
Dene' Wrenn
NPI 1104901065
$760.83
in general payments reported to CMS, 2019-2025
15 companies · $92.01 in 2025
The $92.01 reported for 2025 was less than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2021: $56.85 · 2023: $163 · 2025: $92.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $254.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $171.67 | 2019 | |
| Merck Sharp & Dohme LLC | $166.20 | 2019-2023 | Keytruda |
| Clovis Oncology, INC. | $130.61 | 2019 | |
| Smith+Nephew, INC. | $37.56 | 2019-2025 | Collagenase Santyl |
| Glaxosmithkline, LLC. | $34.91 | 2023 | Jemperli, Zejula |
| Amgen INC. | $33.40 | 2021-2023 | Lumakras |
| Caris Mpi, INC. | $31.19 | 2025 | Mi Cancer Seek |
| Immunogen, INC. | $28.72 | 2023 | Elahere |
| Dexcom, INC. | $21.88 | 2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $21.60 | 2021 | |
| G1 Therapeutics, INC. | $21.48 | 2023 | Cosela |
| Seagen INC. | $17.42 | 2023 | Tukysa |
| Verastem, INC. | $16.96 | 2025 | Avmapki Fakzynja Co-Pack |
| Immunocore Limited | $15.09 | 2023 | Kimmtrak |
| Baxter Healthcare | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dene' Wrenn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.